Omalizumab is an anti-IgE monoclonal antibody used in severe allergic asthma. Herein, we describe a case of eosinophilic granulomatosis with polyangiitis, which manifested 3 months after initiation of omalizumab therapy, while maintenance corticosteroid therapy dose was unchanged.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323353 | PMC |
| http://dx.doi.org/10.1136/bcr-2020-240078 | DOI Listing |
Publication Analysis
Top Keywords
eosinophilic granulomatosis
8
granulomatosis polyangiitis
8
omalizumab-associated eosinophilic
4
polyangiitis coincidence?
4
coincidence? omalizumab
4
omalizumab anti-ige
4
anti-ige monoclonal
4
monoclonal antibody
4
antibody severe
4
severe allergic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!